- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01226498
Effects of Blood Transfusion in Healthy Volunteers
Effects of Duration of Stored Red Blood Cell Transfusion on Physiological Parameters and Inflammatory Mediators in Healthy Adult Volunteers
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
The objective of this study is to assess effects of the storage of PRBC on endothelial function, inflammation and platelet activation in healthy volunteers.
The present study consists of two parts. During one phase of the study, 10 healthy human volunteers will donate a unit of blood, which will be leukoreduced and stored in Additive Solutions-1 (AS-1), and then transfused back to the subjects after 2 days of storage at 4º C in the MGH Blood Bank. The other part of the study consists in the collection of a unit of blood from the same volunteers, but which will be transfused back to the same subject after 40 days of storage. There will be a break of 2 week period in between these 2 study phases. The order of these 2 study parts will be randomized.
We hypothesize that old red blood cells stored under conventional conditions may trigger a complex, pro-inflammatory, pro-thrombotic and vasoconstriction response. We will compare the response to PRBC stored for 2 days with the response to PRBC stored for 40 days in the same healthy volunteers. We will monitor/measure the following markers/parameters:
- Endothelium-mediated changes in vascular (arterial) tone
- Tissue oxygen saturation will be continuously assessed during and after blood transfusion
- Hemolysis as quantified by changes in plasma haptoglobin level, plasma free hemoglobin, LDH level, bilirubin level, iron level, ferritin, and transferrin
- Changes of plasma and red blood cell levels of circulating nitrate, nitrite, RXNO, RNNO, NO-heme
- Concentration of cytokines, such as IL-6, IL-8, IL-10, IL-12, TNF, IFN-γ
- Activation of platelets through circulating P-selectin expression on platelets
- Activation of inflammatory lipid mediators
- Changes in gene expression profiling analyzing RNA microarray of circulating leukocytes
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02114
- Massachusetts General Hospital (MGH)
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Have a photo ID
- Body mass index (BMI) <25 kg/m2 and >18 kg/m2
- Fasting for 8 hours prior to enrollment in the study (a sip of water or brushing teeth in the morning are allowed)
- Feel well the day of blood donation
- Normal physical exam and normal blood test as indicated:
- WBC 4.5-11.0 th/cmm
- HGB 12.5-17.5 gm/dl
- PLT 150-400 th/cumm
- Plasma Sodium 135-145 mmol/L
- Plasma Potassium 3.4-4.8 mmol/L
- Plasma Chloride 98-108 mmol/L
- Plasma Carbon Dioxide 23.0-31.9 mmol/L
- Plasma Urea Nitrogen 8-25 mg/dl
- Plasma Creatinine 0.60-1.50 mg/dl
- Plasma Glucose 70-110 mg/dl
- Transaminase-SGPT 10-55 U/L
- Transaminase-SGOT 10-40 U/L
Exclusion Criteria:
- Psychiatric disturbances such as anxiety, depression, schizophrenia requiring pharmacological treatment or hospitalization in the last year
- Systemic disease with or without any functional limitation
- controlled hypertension
- controlled diabetes without systemic effects
- Pregnancy determined by urine pregnancy test, detecting presence of human chorionic gonadotropin (hCG), or less than six weeks postpartum
- Active smoking. Volunteers may be enrolled if they quit smoking for more than 1 year
- Excess alcohol use: more than ½ L/day of wine consumption or equivalent
- Any current use of a medication other than: Over-the-counter oral medications, herbal remedies, nutritional supplements, and oral contraceptives
- Antibiotic use within 48 hours of blood donation
- Use of NSAIDS, corticosteroids, aspirin during the past 7 days
- Dental work within 24 hours prior to the donation
- Received or donated blood in the last 4 months
- Have had any forms of cancer with the exceptions of basal cell skin cancer or treatment for in situ cervical cancer
- Currently enrolled in another research study
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Scienza basilare
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione incrociata
- Mascheramento: Separare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Fresh blood auto-transfusion
|
Withdrawal from 10 Healthy volunteers of one unit of red blood cells and auto-transfusion after 3 days for one arm of the study, after 40 days for the other.
Participants are enrolled in both arms of the study.
|
|
Sperimentale: Old blood auto-transfusion
|
Withdrawal from 10 Healthy volunteers of one unit of red blood cells and auto-transfusion after 3 days for one arm of the study, after 40 days for the other.
Participants are enrolled in both arms of the study.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
Endothelial function
Lasso di tempo: Baseline
|
Baseline
|
|
Endothelial function
Lasso di tempo: 10 min after transfusion
|
10 min after transfusion
|
|
Endothelial function
Lasso di tempo: 1h after transfusion
|
1h after transfusion
|
|
Endothelial function
Lasso di tempo: 4h after transfusion
|
4h after transfusion
|
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
Hemolysis
Lasso di tempo: Baseline
|
Baseline
|
|
NO metabolites
Lasso di tempo: Baseline
|
Baseline
|
|
Concentration of cytokines
Lasso di tempo: Baseline
|
Baseline
|
|
Activation of platelets
Lasso di tempo: Baseline
|
Baseline
|
|
Activation of inflammatory lipid mediators
Lasso di tempo: Baseline
|
Baseline
|
|
Changes in gene expression
Lasso di tempo: Baseline
|
Baseline
|
|
Hemolysis
Lasso di tempo: 10 min after transfusion
|
10 min after transfusion
|
|
NO metabolites
Lasso di tempo: 10 min after transfusion
|
10 min after transfusion
|
|
Concentration of cytokines
Lasso di tempo: 10 min after transfusion
|
10 min after transfusion
|
|
Activation of platelets
Lasso di tempo: 10 min after transfusion
|
10 min after transfusion
|
|
Activation of inflammatory lipid mediators
Lasso di tempo: 10 min after transfusion
|
10 min after transfusion
|
|
Changes in gene expression
Lasso di tempo: 10 min after transfusion
|
10 min after transfusion
|
|
Hemolysis
Lasso di tempo: 1h after transfusion
|
1h after transfusion
|
|
NO metabolites
Lasso di tempo: 1h after transfusion
|
1h after transfusion
|
|
Concentration of cytokines
Lasso di tempo: 1h after transfusion
|
1h after transfusion
|
|
Activation of platelets
Lasso di tempo: 1h after transfusion
|
1h after transfusion
|
|
Activation of inflammatory lipid mediators
Lasso di tempo: 1h after transfusion
|
1h after transfusion
|
|
Changes in gene expression
Lasso di tempo: 1h after transfusion
|
1h after transfusion
|
|
Hemolysis
Lasso di tempo: 2h after transfusion
|
2h after transfusion
|
|
NO metabolites
Lasso di tempo: 2h after transfusion
|
2h after transfusion
|
|
Concentration of cytokines
Lasso di tempo: 2h after transfusion
|
2h after transfusion
|
|
Activation of platelets
Lasso di tempo: 2h after transfusion
|
2h after transfusion
|
|
Activation of inflammatory lipid mediators
Lasso di tempo: 2h after transfusion
|
2h after transfusion
|
|
Changes in gene expression
Lasso di tempo: 2h after transfusion
|
2h after transfusion
|
|
Hemolysis
Lasso di tempo: 4h after transfusion
|
4h after transfusion
|
|
NO metabolites
Lasso di tempo: 4h after transfusion
|
4h after transfusion
|
|
Concentration of cytokines
Lasso di tempo: 4h after transfusion
|
4h after transfusion
|
|
Activation of platelets
Lasso di tempo: 4h after transfusion
|
4h after transfusion
|
|
Activation of inflammatory lipid mediators
Lasso di tempo: 4h after transfusion
|
4h after transfusion
|
|
Changes in gene expression
Lasso di tempo: 4h after transfusion
|
4h after transfusion
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Warren M Zapol, MD, Massachusetts General Hospital, DACCPM
Pubblicazioni e link utili
Pubblicazioni generali
- Koch CG, Li L, Sessler DI, Figueroa P, Hoeltge GA, Mihaljevic T, Blackstone EH. Duration of red-cell storage and complications after cardiac surgery. N Engl J Med. 2008 Mar 20;358(12):1229-39. doi: 10.1056/NEJMoa070403.
- Gladwin MT, Lancaster JR Jr, Freeman BA, Schechter AN. Nitric oxide's reactions with hemoglobin: a view through the SNO-storm. Nat Med. 2003 May;9(5):496-500. doi: 10.1038/nm0503-496. No abstract available.
- Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation. 1993 May;87(5):1468-74. doi: 10.1161/01.cir.87.5.1468.
- Hendrickson JE, Hillyer CD. Noninfectious serious hazards of transfusion. Anesth Analg. 2009 Mar;108(3):759-69. doi: 10.1213/ane.0b013e3181930a6e.
- Bennett-Guerrero E, Veldman TH, Doctor A, Telen MJ, Ortel TL, Reid TS, Mulherin MA, Zhu H, Buck RD, Califf RM, McMahon TJ. Evolution of adverse changes in stored RBCs. Proc Natl Acad Sci U S A. 2007 Oct 23;104(43):17063-8. doi: 10.1073/pnas.0708160104. Epub 2007 Oct 11.
- Cardillo C, Kilcoyne CM, Cannon RO 3rd, Panza JA. Interactions between nitric oxide and endothelin in the regulation of vascular tone of human resistance vessels in vivo. Hypertension. 2000 Jun;35(6):1237-41. doi: 10.1161/01.hyp.35.6.1237.
- Nagasaka Y, Fernandez BO, Garcia-Saura MF, Petersen B, Ichinose F, Bloch KD, Feelisch M, Zapol WM. Brief periods of nitric oxide inhalation protect against myocardial ischemia-reperfusion injury. Anesthesiology. 2008 Oct;109(4):675-82. doi: 10.1097/ALN.0b013e318186316e.
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Altri numeri di identificazione dello studio
- 2010P000961
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Trasfusione di sangue, autologo
-
Andrew Hantel, MDNon ancora reclutamentoMieloma multiplo | Cancro al seno triplo negativo | Duffy Blood Group, Chemokine Receptor Gene Mutation | Duffy Blood Group, Chemokine Receptor Gene C.-67T>CStati Uniti
-
Hangzhou Agile Groups Network Technology Co., Ltd.CompletatoAnemia | Condizione della pelle | Sindrome da carenza di blind Qi-BLOODCina
-
Zhongnan HospitalReclutamentoMicrotrapianto di UCB (Cord Blood) nel trattamento della leucemia mieloide acuta (AML) di nuova diagnosiCina
Prove cliniche su Red blood Cells auto-transfusion
-
Ohio State University Comprehensive Cancer CenterReclutamentoLeucemia linfocitica cronica refrattaria | Linfoma non Hodgkin ricorrente | Linfoma non Hodgkin refrattario | Leucemia linfoblastica acuta ricorrente | Leucemia linfoblastica acuta refrattaria | Leucemia linfocitica cronica ricorrente | Linfoma linfoblastico refrattario | Leucemia linfocitica cronica... e altre condizioniStati Uniti